Thiol-mediated inhibition of FAS and CD2 apoptotic signaling in activated human peripheral T cells.
Fas and CD2 receptors can transduce apoptotic signals through two independent biochemical pathways. In this study, we first evaluated the role of intracellular GSH in these signaling pathways by inducing variations in the GSH pool of activated peripheral T lymphocytes. Increasing the concentration of intracellular GSH by means of N-acetyl-L-cysteine (NAC) and GSH ethyl ester (OEt) resulted in total protection against cell death, while inhibiting GSH synthesis with buthionine sulfoximine (BSO) greatly enhanced cell sensitivity to Fas and CD2 apoptotic signaling. The protection exerted by NAC and GSH OEt was essentially based on their capacity to establish an intracellular reducing environment as it still occurred in BSO-treated cells. Thiol-containing compounds (cysteine, captopril, D-penicillamine and 2-mercaptoethanol) inhibited apoptosis while a series of non-thiol antioxidants (including catalase and vitamin E) failed to do so, suggesting that protection was secondary to thiols/disulfides exchange reactions at the level of cysteine residues in proteins and not to detoxification of reactive oxygen intermediates. This conclusion was further supported by the finding that no enhanced generation of O.-2 and H2O2 could be detected in cells experiencing early stages of apoptosis such as a decreased concentration of intracellular GSH and cell shrinkage. Also, protection occurred in the presence of protein synthesis inhibitors, indicating that it was due to post-translational sulfhydryl redox regulation of critical molecules involved in the apoptotic cascade. These data suggest that GSH, the most abundant intracellular thiol antioxidant, may be important in counteracting Fas- and CD2-mediated apoptosis of T lymphocytes.
Déas
O
O
Equipe d'Immunologie Cellulaire et de transplantation, UPR 420 CNRS, Villejuif, France.
Dumont
C
C
Mollereau
B
B
Métivier
D
D
Pasquier
C
C
Bernard-Pomier
G
G
Hirsch
F
F
Charpentier
B
B
Senik
A
A
D000111:Acetylcysteine / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects / Q000276:immunology*; D019328:Buthionine Sulfoximine / Q000494:pharmacology; D018801:CD2 Antigens / Q000187:drug effects* / Q000502:physiology; D002478:Cells, Cultured; D003513:Cycloheximide / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D005260:Female; D005978:Glutathione / Q000031:analogs & derivatives / Q000096:biosynthesis / Q000187:drug effects / Q000494:pharmacology; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects*; D008297:Male; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology*; D013438:Sulfhydryl Compounds / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D019014:fas Receptor / Q000187:drug effects* / Q000502:physiology
D000975:Antioxidants; D018801:CD2 Antigens; D013438:Sulfhydryl Compounds; D019014:fas Receptor; D003609:Dactinomycin; D019328:Buthionine Sulfoximine; C042431:S-ethyl glutathione; D003513:Cycloheximide; D005978:Glutathione; D000111:Acetylcysteine